The estimated Net Worth of Jonathan Elliott Dickinson is at least $3.4 Milion dollars as of 31 January 2022. Jonathan Dickinson owns over 7,375 units of Incyte stock worth over $1,907,410 and over the last 5 years Jonathan sold INCY stock worth over $1,494,941.
Jonathan has made over 2 trades of the Incyte stock since 2020, according to the Form 4 filled with the SEC. Most recently Jonathan sold 7,375 units of INCY stock worth $547,151 on 31 January 2022.
The largest trade Jonathan's ever made was selling 9,000 units of Incyte stock on 22 June 2020 worth over $947,790. On average, Jonathan trades about 862 units every 31 days since 2020. As of 31 January 2022 Jonathan still owns at least 30,214 units of Incyte stock.
You can see the complete history of Jonathan Dickinson stock trades at the bottom of the page.
Jonathan's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... oraz Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: